The AMBITION study was a randomised, double-blind Phase IIIb/IV study designed to compare the efficacy and safety of Volibris (ambrisentan)...
The European Commission has approved a variation to expand the current therapeutic indication for Volibris (ambrisentan), from Glaxo Smith Kline/Gilead,...
Sanofi and Eli Lilly and Company announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently...
The CHMP in the EU has recommended approval of Cialis (tadalafil), from Eli Lilly and Co, for once daily use...